|
•
|
“First Phase 3 Results From CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma”
|
•
|
“CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma”
|
•
|
“Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T – at least 5-year follow-up in LEGEND-2”
|
|
LEGEND BIOTECH CORPORATION
|
||
|
|
|
|
Date: April 21, 2023
|
By:
|
/s/ Ying Huang
|
|
|
Name:
|
Ying Huang, Ph.D.
|
|
|
Title:
|
Chief Executive Officer
|